Literature DB >> 6611231

Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis.

A Bionda, M H De Baets, S J Tzartos, J M Lindstrom, W O Weigle, A N Theophilopoulos.   

Abstract

We have studied the isoelectric focusing pattern of antibodies expressed in rats with experimental autoimmune myasthenia gravis (EAMG) induced by immunization with acetylcholine receptors (AChR) purified from Torpedo californica. Sera or tissue eluates were obtained at intervals in the course of disease and subjected to isoelectric focusing. Subsequently, the focused antibodies were detected by autoradiography of gels labelled with 125I-alpha-bungarotoxin conjugated AChR. Reverse electrofocusing was used to separate complexes of antibody and AChR formed in vivo, thereby allowing detection of the full spectrotype (banding pattern). As little as 1.1 X 10(-12) moles of monoclonal antibodies (MoAbs) to AChR yielded distinct bands of radiolabelled antigen binding by this technique. The anti-AChR MoAbs studied showed a multitude of bands localized in neutral to alkaline position. The clonotypes expressed in late post-immunization sera were compared to early sera. The spectrotypes of immunized Lewis and Brown Norway rats were not identical. In early sera most of the isoelectric focusing bands were specific for T. californica AChR, whereas in late sera further expansion of the repertoire produced bands that reacted with rat muscle AChR as well. The focused bands that bound rat AChR also bound T. californica AChR. The anti-AChR antibodies eluted from muscles of rats with EAMG showed similar binding patterns to anti-receptor antibodies in rats' sera. These results indicate that the antibody specificities detected in serum are the same specificities which are effective in binding to muscle AChR in vivo. Minor specificities of serum anti-receptor antibodies are not disproportionally represented in the antibodies actually bound at the neuromuscular junction in EAMG.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6611231      PMCID: PMC1536098     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Characterization of acetylcholine receptor-rich and acetylcholinesterase-rich membrane particles from Torpedo californica electroplax.

Authors:  K Reed; R Vandlen; J Bode; J Duguid; M A Raftery
Journal:  Arch Biochem Biophys       Date:  1975-03       Impact factor: 4.013

2.  Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations.

Authors:  A G Engel; E H Lambert; F M Howard
Journal:  Mayo Clin Proc       Date:  1977-05       Impact factor: 7.616

3.  Detection of isoelectric focused antibody by autoradiography and hemolysis of antigen-coated erythrocytes. A comparison of methods.

Authors:  D E Briles; J M Davie
Journal:  J Immunol Methods       Date:  1975-10       Impact factor: 2.303

Review 4.  Serum acetylcholine-receptor antibodies in myasthenia gravis.

Authors:  R R Almon; S H Appel
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

5.  Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.

Authors:  J M Lindstrom; M E Seybold; V A Lennon; S Whittingham; D D Duane
Journal:  Neurology       Date:  1976-11       Impact factor: 9.910

6.  Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis.

Authors:  K Sahashi; A G Engel; J M Linstrom; E H Lambert; V A Lennon
Journal:  J Neuropathol Exp Neurol       Date:  1978 Mar-Apr       Impact factor: 3.685

7.  Modulation of acetylcholine receptor by antibody against the receptor.

Authors:  S Heinemann; S Bevan; R Kullberg; J Lindstrom; J Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

8.  Myasthenic immunoglobulin accelerates acetylcholine receptor degradation.

Authors:  I Kao; D B Drachman
Journal:  Science       Date:  1977-04-29       Impact factor: 47.728

9.  Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model.

Authors:  A G Engel; J M Lindstrom; E H Lambert; V A Lennon
Journal:  Neurology       Date:  1977-04       Impact factor: 9.910

10.  Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.

Authors:  J M Lindstrom; B L Einarson; V A Lennon; M E Seybold
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Specificities of autoantibodies in autoimmune receptor diseases.

Authors:  M H De Baets
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

2.  Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies.

Authors:  F W Miller; S A Twitty; T Biswas; P H Plotz
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

3.  Effects of the rate of acetylcholine receptor synthesis on the severity of experimental autoimmune myasthenia gravis.

Authors:  M H De Baets; J Verschuuren; M R Daha; P J van Breda Vriesman
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

4.  Distinct clonotypes of anti-DNA antibodies in mice with lupus nephritis.

Authors:  H Yoshida; M Yoshida; S Izui; P H Lambert
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

5.  Naturally occurring antibodies to bovine and human retinal S antigen: a comparison between uveitis patients and healthy volunteers.

Authors:  J V Forrester; D I Stott; K M Hercus
Journal:  Br J Ophthalmol       Date:  1989-02       Impact factor: 4.638

6.  Long term spectrotypic and idiotypic stability of thyroglobulin autoantibodies in patients with Hashimoto's thyroiditis.

Authors:  P J Delves; I M Roitt
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.